Estados Unidos · Bolsa y Finanzas · Yahoo Finance

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

Publicado por Yahoo Finance · Estados Unidos hace 8 h

Continue » Eli Lilly's Zepbound is currently the leading medicine in the anti-obesity market largely because it is more effective than its main competitor, Novo Nordisk 's (NYSE:…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

También te puede interesar

David Robinson says a sense of 'cognitive dissonance' led him to leave OpenAI

The 5 most expensive basketball cards ever sold

Wall Street closed in the red as investors focused on yields and the Fed minutes

Global Diesel Crunch Fuels New Wave of Energy Nationalism

Tether Signs Deal With Kazakhstan's Central Bank to Explore a Stablecoin and Tokenized Assets

Apollo, banks in talks to finance SpaceX's $40 billion Nvidia GPU purchase

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

Compartir

También te puede interesar

David Robinson says a sense of 'cognitive dissonance' led him to leave OpenAI

The 5 most expensive basketball cards ever sold

Wall Street closed in the red as investors focused on yields and the Fed minutes

Global Diesel Crunch Fuels New Wave of Energy Nationalism

Tether Signs Deal With Kazakhstan's Central Bank to Explore a Stablecoin and Tokenized Assets

Apollo, banks in talks to finance SpaceX's $40 billion Nvidia GPU purchase